{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:39:10Z","timestamp":1776317950793,"version":"3.50.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T00:00:00Z","timestamp":1431475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0126347","type":"journal-article","created":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T14:03:39Z","timestamp":1431525819000},"page":"e0126347","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":38,"title":["Long-Term Frequent Use of Non-Steroidal Anti-Inflammatory Drugs Might Protect Patients with Ankylosing Spondylitis from Cardiovascular Diseases: A Nationwide Case-Control Study"],"prefix":"10.1371","volume":"10","author":[{"given":"Wen-Chan","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsan-Teng","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeng-Hsien","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Chin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ching","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2","article-title":"Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia","volume":"43","author":"F Wolfe","year":"2000","journal-title":"Arthritis Rheum"},{"key":"ref2","first-page":"1020","article-title":"Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis","volume":"27","author":"T Pincus","year":"2000","journal-title":"J Rheumatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7326\/0003-4819-115-10-787","article-title":"Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis","volume":"115","author":"SE Gabriel","year":"1991","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-114-4-257","article-title":"Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons","volume":"114","author":"MR Griffin","year":"1991","journal-title":"Ann Intern Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"MM Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"FE Silverstein","year":"2000","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"C Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"RS Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"SD Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","article-title":"Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery","volume":"352","author":"NA Nussmeier","year":"2005","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","article-title":"Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis","volume":"330","author":"J Hippisley-Cox","year":"2005","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.165.9.978","article-title":"Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study","volume":"165","author":"SP Johnsen","year":"2005","journal-title":"Arch Intern Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1074248407312990","article-title":"Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease","volume":"13","author":"CH Hennekens","year":"2008","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"JC12","DOI":"10.7326\/0003-4819-159-8-201310150-02012","article-title":"Review: NSAIDs increase GI and CV events; coxibs increase mortality","volume":"159","author":"E Lader","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref15","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"33","author":"C Han","year":"2006","journal-title":"J Rheumatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/keg175","article-title":"Tackling ischaemic heart disease in rheumatoid arthritis","volume":"42","author":"GD Kitas","year":"2003","journal-title":"Rheumatology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/ard.2010.142133","article-title":"Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives","volume":"70","author":"GD Kitas","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semarthrit.2012.12.002","article-title":"The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review","volume":"43","author":"SR Schoenfeld","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"JM Esdaile","year":"2001","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/acr.20408","article-title":"Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis","volume":"63","author":"A Bremander","year":"2011","journal-title":"Arthritis Care Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1002\/art.30581","article-title":"Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study","volume":"63","author":"SM Szabo","year":"2011","journal-title":"Arthritis Rheum"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399405009154","article-title":"Inflammation and atherosclerosis in rheumatoid arthritis","volume":"7","author":"RJ Stevens","year":"2005","journal-title":"Expert Rev Mol Med"},{"key":"ref23","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"LT Jacobsson","year":"2005","journal-title":"J Rheumatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"JD Greenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"WG Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/acr.22166","article-title":"TNF-alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis patients","volume":"66","author":"A Bili","year":"2014","journal-title":"Arthritis Care Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"ME Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/archinte.162.10.1105","article-title":"Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis","volume":"162","author":"DJ Watson","year":"2002","journal-title":"Arch Intern Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","article-title":"Risk of cardiovascular events and rofecoxib: cumulative meta-analysis","volume":"364","author":"P Juni","year":"2004","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.amjmed.2005.10.056","article-title":"Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs","volume":"119","author":"SR Salpeter","year":"2006","journal-title":"Am J Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/ard.2007.076760","article-title":"Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients","volume":"68","author":"NJ Goodson","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2012-203137","article-title":"Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study","volume":"73","author":"J Lindhardsen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"A Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis","volume":"71","author":"F Kroon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"71","author":"D Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1136\/annrheumdis-2012-201844","article-title":"NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms?","volume":"71","author":"N Haroon","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0126347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T22:42:54Z","timestamp":1540334574000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0126347"}},"subtitle":[],"editor":[{"given":"Shang-Zhong","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,13]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0126347","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,13]]}}}